A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome - 25/02/16
, Barbara T. Isemann, BSPharm 2, Scott L. Wexelblatt, MD 1, 3, Jareen Meinzen-Derr, PhD 4, Jason R. Wiles, MD 1, Sharon Harvey, BSN 2, Henry T. Akinbi, MD 1, 3Abstract |
Objectives |
To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol.
Study design |
This retrospective cohort analysis evaluated infants who received pharmacotherapy for NAS at 6 hospitals in Southwest Ohio from January 2012 through August 2014. A single neonatology provider group used a standardized methadone protocol across all 6 hospitals. However, at one of the sites, infants were managed with a buprenorphine protocol unless they had experienced chronic in utero exposure to methadone. Linear mixed models were used to calculate adjusted mean duration of opioid treatment and length of inpatient hospitalization with 95% CIs in infants treated with oral methadone compared with sublingual buprenorphine. The use of adjunct therapy was examined as a secondary outcome.
Results |
A total of 201 infants with NAS were treated with either buprenorphine (n = 38) or methadone (n = 163) after intrauterine exposure to short-acting opioids or buprenorphine. Buprenorphine therapy was associated with a shorter course of opioid treatment of 9.4 (CI 7.1-11.7) vs 14.0 (12.6-15.4) days (P < .001) and decreased hospital stay of 16.3 (13.7-18.9) vs 20.7 (19.1-22.2) days (P < .001) compared with methadone therapy. No difference was detected in the use of adjunct therapy (23.7% vs 25.8%, P = .79) between treatment groups.
Conclusion |
The choice of pharmacotherapeutic agent is an important determinant of hospital outcomes in infants with NAS. Sublingual buprenorphine may be superior to methadone for management of NAS in infants with select intrauterine opioid exposures.
Le texte complet de cet article est disponible en PDF.Keyword : NAS
Plan
| Supported by the Cincinnati Children's Hospital Perinatal Institute. Support for data collection was provided by the Ohio Office of Health Transformation (G1213070561). REDCap technology was provided through Center for Clinical and Translational Science and Training (UL1-RR026314). The authors declare no conflicts of interest. |
Vol 170
P. 39 - mars 2016 Retour au numéro
Article précédent
- School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, and Lifestyle Study
- Nwando Eze, Lynne M. Smith, Linda L. LaGasse, Chris Derauf, Elana Newman, Amelia Arria, Marilyn A. Huestis, Sheri A. Della Grotta, Lynne M. Dansereau, Charles Neal, Barry M. Lester
- Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial
- Diane C. Chugani, Harry T. Chugani, Max Wiznitzer, Sumit Parikh, Patricia A. Evans, Robin L. Hansen, Ruth Nass, James J. Janisse, Pamela Dixon-Thomas, Michael Behen, Robert Rothermel, Jacqueline S. Parker, Ajay Kumar, Otto Muzik, David J. Edwards, Deborah Hirtz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?